Hannah Johnson
Family · Philadelphia, MSNPI 1588194708
Payments from drug & device makers
Across 328 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$829
- Lilly USA, LLC$595
- Bayer$385
- GSK$324
- Amgen$317
- plus $1K from 17 others
What the payments were for
- Food & beverage$5,244100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 84 | $1,442 |
| AbbVie | 62 | $829 |
| Lilly USA, LLC | 43 | $595 |
| Bayer | 22 | $385 |
| GSK | 18 | $324 |
| Amgen | 21 | $317 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $201 |
| Boehringer Ingelheim | 11 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $144 |
| Novo Nordisk | 7 | $127 |
| Pfizer | 6 | $106 |
| Sunovion Pharmaceuticals Inc. | 4 | $91 |
| Abbott | 6 | $91 |
| Novartis | 4 | $84 |
| Eisai Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $33 |
| Johnson & Johnson | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Medtronic | 1 | $19 |
| BD | 1 | $18 |
How this compares
$5,244 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 111 | $78,532 |
| JardianceEmpagliflozin | 40 | $44,645 |
| MounjaroTirzepatide | 37 | $44,064 |
| RybelsusSemaglutide | 18 | $39,719 |
| EliquisApixaban | 50 | $38,011 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,843 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $28,182 |
| KerendiaFinerenone | 24 | $20,714 |
| JanuviaSitagliptin Phosphate | 29 | $20,244 |
| LinzessLinaclotide | 15 | $15,788 |
| TrulicityDulaglutide | 11 | $14,540 |
| MyrbetriqMirabegron | 25 | $13,678 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $13,163 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $9,813 |
| Repatha SureclickEvolocumab | 15 | $7,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,442 | $106,714151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $595 | $58,60448 claims |
| Boehringer IngelheimJardiance | $173 | $44,64540 claims |
| PfizerEliquis, Premarin | $106 | $41,56467 claims |
| Novo NordiskRybelsus | $127 | $39,71918 claims |
| GSKTrelegy Ellipta | $324 | $32,84337 claims |
| BayerKerendia | $385 | $20,71424 claims |
| AbbVieLinzess, Synthroid | $829 | $16,95039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Philadelphia
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.